Literature DB >> 4014387

Iris melanomas.

L J Geisse, D M Robertson.   

Abstract

Most iris tumors behave benignly, reflecting their small size and the high proportion of nevi and spindle A melanomas. Of 1,043 reported iris melanomas, 31 metastasized (3%). Metastasis from a spindle A melanoma is not known to occur despite documented growth and local recurrence after excision. If known spindle A melanomas are excluded from all reported spindle cell tumors of the iris, the rate of metastasis for spindle cell tumors is 2.6%. Mixed-cell melanomas have a metastasis rate of 10.5% and epithelioid melanomas a rate of 6.9%. The interval between the histologic diagnosis and death from metastases ranged from three months to 12 years, with an average of 6.5 years. Five- and ten-year mortality rates for different cell types cannot be ascertained. Iris angiography may be useful in defining the limits of tumor involvement but is of uncertain value in differentiating benignancy from malignancy. Of the 31 cases with metastases, 21 included information on the type of surgical procedure used to obtain the histologic diagnosis. In 13 of the 21 cases (62%), the tumors were initially involved with either incomplete excision or inadvertent transection before enucleation.

Entities:  

Mesh:

Year:  1985        PMID: 4014387     DOI: 10.1016/s0002-9394(14)76028-3

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  19 in total

1.  Proton therapy of iris melanoma with 50 CGE : Influence of target volume on clinical outcome.

Authors:  Aline I Riechardt; Bettina Karle; Dino Cordini; Jens Heufelder; Volker Budach; Antonia M Joussen; Johannes Gollrad
Journal:  Strahlenther Onkol       Date:  2017-06-19       Impact factor: 3.621

2.  Progression of an iris melanoma over 41 years.

Authors:  D G Charteris
Journal:  Br J Ophthalmol       Date:  1990-09       Impact factor: 4.638

Review 3.  Rare presentations of primary melanoma and special populations: a systematic review.

Authors:  Lisa A Kottschade; Travis E Grotz; Roxana S Dronca; Diva R Salomao; Jose S Pulido; Nabil Wasif; James W Jakub; Sanjay P Bagaria; Riten Kumar; Judith S Kaur; Shane Y Morita; Steven L Moran; Jesse T Nguyen; Emily C Nguyen; Jennifer L Hand; Lori A Erickson; Jerry D Brewer; Christian L Baum; Robert C Miller; David L Swanson; Val Lowe; Svetomir N Markovic
Journal:  Am J Clin Oncol       Date:  2014-12       Impact factor: 2.339

Review 4.  Prognosis in ocular melanoma.

Authors:  J Hungerford
Journal:  Br J Ophthalmol       Date:  1989-09       Impact factor: 4.638

5.  Melanoma of the iris.

Authors: 
Journal:  Br J Ophthalmol       Date:  1989-08       Impact factor: 4.638

6.  Optical Coherence Tomography Angiography Characteristics of Iris Melanocytic Tumors.

Authors:  Alison H Skalet; Yan Li; Chen D Lu; Yali Jia; ByungKun Lee; Lennart Husvogt; Andreas Maier; James G Fujimoto; Charles R Thomas; David Huang
Journal:  Ophthalmology       Date:  2016-11-14       Impact factor: 12.079

7.  Iris pigmentation and pigmented lesions: an ultrastructural study.

Authors:  R C Eagle
Journal:  Trans Am Ophthalmol Soc       Date:  1988

8.  Irradiating iris tumours.

Authors:  I Rennie
Journal:  Br J Ophthalmol       Date:  1995-04       Impact factor: 4.638

9.  Conventional diagnostic ultrasound of iris lesions.

Authors:  A M Verbeek
Journal:  Doc Ophthalmol       Date:  1995       Impact factor: 2.379

10.  Proton beam therapy for presumed and confirmed iris melanomas: a review of 36 cases.

Authors:  Ahmed Rahmi; Hamid Mammar; Juliette Thariat; Gaelle Angellier; Joel Herault; Pierre Chauvel; Laurent Kodjikian; Philippe Denis; Jean Daniel Grange
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-07-20       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.